MENU
+Compare
CDMO
Stock ticker: NASDAQ
AS OF
Jan 14, 04:59 PM (EDT)
Price
$12.42
Change
-$0.01 (-0.08%)
Capitalization
794.42M

CDMO Avid Bioservices Forecast, Technical & Fundamental Analysis

Engages in the developing and manufacturing of monoclonal antibody therapeutics

Industry Biotechnology
CDMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CDMO with price predictions
Jan 08, 2025

CDMO in +0.33% Uptrend, growing for three consecutive days on January 06, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CDMO advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on CDMO as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDMO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CDMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.730) is normal, around the industry mean (15.212). P/E Ratio (0.000) is within average values for comparable stocks, (87.972). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.839). CDMO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (5.249) is also within normal values, averaging (258.672).

View a ticker or compare two or three
CDMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CDMO is expected to report earnings to fall 79.00% to -5 cents per share on March 17

Avid Bioservices CDMO Stock Earnings Reports
Q1'25
Est.
$-0.06
Q4'24
Missed
by $0.17
Q3'24
Missed
by $0.04
Q2'24
Missed
by $1.90
Q1'24
Missed
by $0.04
The last earnings report on December 10 showed earnings per share of -27 cents, missing the estimate of -10 cents. With 1.57M shares outstanding, the current market capitalization sits at 794.42M.
A.I. Advisor
published General Information

General Information

Engages in the developing and manufacturing of monoclonal antibody therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
14191 Myford Road
Phone
+1 714 508-6100
Employees
365
Web
https://www.avidbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AGGWX12.580.29
+2.36%
American Century Global Gold R
TRZVX52.760.84
+1.62%
T. Rowe Price Small-Cap Value Z
CFMVX23.920.26
+1.10%
Commerce MidCap Value
DIFHX11.940.03
+0.25%
MFS Diversified Income R6
MENCX7.720.01
+0.13%
Madison Covered Call & Equity Income C

CDMO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CDMO has been loosely correlated with AXON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CDMO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDMO
1D Price
Change %
CDMO100%
-0.08%
AXON - CDMO
49%
Loosely correlated
+1.96%
DRMA - CDMO
42%
Loosely correlated
+4.35%
ARRY - CDMO
41%
Loosely correlated
+2.12%
VCYT - CDMO
38%
Loosely correlated
-4.02%
MGTX - CDMO
35%
Loosely correlated
-2.37%
More